A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,997

Participants

Timeline

Start Date

February 28, 1999

Primary Completion Date

July 31, 2001

Study Completion Date

July 31, 2001

Conditions

MeaslesMumpsRubellaVaricella

Interventions

BIOLOGICAL

Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live

0.5 mL subcutaneous injection of one of three sub-lots on Day 0

BIOLOGICAL

Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)

0.5 mL subcutaneous injection on Day 0

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY